C84.62 Anaplastic large cell lymphoma, ALK-positive, intrathoracic lymph nodes

Name of the Condition

• Anaplastic large cell lymphoma, ALK-positive, intrathoracic lymph nodes (ICD-10 Code: C84.62)

Summary

Anaplastic large cell lymphoma, ALK-positive, intrathoracic lymph nodes (ALCL, ALK-positive) is a rare subtype of non-Hodgkin lymphoma that primarily affects T-lymphocytes. It is characterized by the presence of the anaplastic lymphoma kinase (ALK) protein, resulting from a specific genetic rearrangement. This condition typically presents as a rapidly growing tumor involving the intrathoracic lymph nodes, which include those in the chest cavity. ALCL, ALK-positive is more common in children and young adults and is generally considered aggressive but responsive to targeted therapies.

Causes

The exact cause of ALK-positive ALCL is not fully understood. The disease is driven by a genetic translocation involving the ALK gene, most commonly the t(2;5)(p23;q35) translocation, which results in overexpression of the ALK protein. This abnormal protein promotes uncontrolled cell growth and survival. While the translocation is a key driver, other genetic mutations may contribute to disease development, though specific environmental triggers remain unclear.

Risk Factors

• Age: More common in children and young adults, with a peak incidence in the second and third decades of life.
• Gender: Slightly higher prevalence in males.
• Genetic factors: Presence of the ALK translocation is a primary risk factor.
• Immunosuppression: Weakened immune systems may increase susceptibility.

Symptoms

Symptoms may include enlarged lymph nodes in the chest, cough, shortness of breath, chest pain, fever, night sweats, or unexplained weight loss. The presentation can vary depending on the extent of lymph node involvement and any associated tissue infiltration.

Diagnosis

Diagnosis involves a combination of clinical evaluation, imaging studies (e.g., CT scans of the chest), and biopsy of the affected lymph nodes. Histopathological examination confirms the presence of ALK-positive ALCL, often using immunohistochemistry to detect the ALK protein. Additional tests, such as flow cytometry or genetic analysis, may be performed to rule out other conditions and assess disease extent.

Treatment Options

Treatment typically includes systemic therapies such as chemotherapy, often combined with targeted agents like ALK inhibitors. Radiation therapy may be used for localized disease. The specific regimen depends on the stage of the disease, patient age, and overall health. Clinical trials may be an option for some patients.

Prognosis and Follow-Up

Prognosis varies based on disease stage, response to treatment, and individual factors. ALK-positive ALCL generally has a better prognosis than ALK-negative subtypes, especially in younger patients. Follow-up care includes regular monitoring for recurrence, imaging studies, and blood tests to assess treatment response and detect any complications.

Complications

Potential complications include disease progression, treatment-related side effects (e.g., infection risk from chemotherapy), organ dysfunction due to tumor burden, or long-term effects of therapy. Rarely, the disease may transform into a more aggressive form.

Lifestyle & Prevention

No specific lifestyle changes can prevent ALK-positive ALCL, as the condition is primarily genetic. Maintaining overall health, avoiding known carcinogens, and adhering to recommended cancer screening guidelines may support general well-being. Patients should discuss individual risk factors with their healthcare provider.

When to Seek Professional Help

Seek medical attention if you experience persistent symptoms such as unexplained weight loss, fever, night sweats, or enlarged lymph nodes, especially in the chest area. Early evaluation is important for timely diagnosis and treatment.

Tips for Medical Coders

When coding for C84.62, ensure the documentation specifies "intrathoracic lymph nodes" to confirm the site. Verify that the diagnosis aligns with ALK-positive status, as this differentiates it from other lymphoma subtypes. Accurate coding requires clear documentation of the anatomical location and molecular characteristics.